ANSYS Inc. develops and globally markets engineering simulation software and services widely used by engineers, designers, researchers and students across a broad spectrum of industries and academia. ANSYS Workbench, simulation platform is the company's key product. It provides structural analysis product suite, simulation software solutions for Fluids, Electronics, Semiconductors, and Multiphysics. AIM is a single-window application which integrates structural, fluids and electromagnetics simulation as well as includes all aspects of the simulation workflow. The company's SCADE product suite is a comprehensive solution for embedded software simulation, code production and automated certification. ANSYS provides simulation software for 3D modelling, Systems and academics.ANSYS Cloud combines high-performance computing infrastructure and Microsoft Azure platform with ANSYS software. ANSYS 2019 R1 enables engineers in designing more pervasive simulation solutions across multiple industries....
+See More2018-06-17 10:35:00 Sunday ET
In the past decades, capital market liberalization and globalization have combined to connect global financial markets to allow an ocean of money to flow th
2022-03-15 10:32:00 Tuesday ET
Capital structure theory and practice The genesis of modern capital structure theory traces back to the seminal work of Modigliani and Miller (1958
2019-11-23 08:33:00 Saturday ET
MIT financial economist Simon Johnson rethinks capitalism with better key market incentives. Johnson refers to the recent Business Roundtable CEO statement
2019-04-17 11:34:00 Wednesday ET
Amazon CEO Jeff Bezos admits the fact that antitrust scrutiny remains a primary imminent threat to his e-commerce business empire. In his annual letter to A
2019-03-15 13:36:00 Friday ET
CNBC stock host Jim Cramer recommends both Caterpillar and Home Depot as the U.S. bull market is likely to continue in light of the recent Fed Chair comment
2018-05-07 07:32:00 Monday ET
President Trump seeks to honor his campaign promise of lower U.S. medical costs by forcing higher big-pharma prices in foreign countries such as Canada, Bri